Company intelligence / Profile preview
Otovia Therapeutics
Suzhou, Jiangsu Sheng, Chinaotovia.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
OTOV-101, designed for DFNB9 deafness, began IIT clinical trial in June 2023 with exceptional clinical efficacy. Patients with congenital deafness experienced hearing restoration post-treatment. Clinical data published in Advanced Science in January 2024, marking the world's first formal report on clinical application of gene therapy for deafness. Over 10 patients have been successfully treated, with the longest follow-up exceeding 1.5 years.
- Therapeutic areas
- Neurology
- Modalities
- AAV-based gene therapyGene editingGene therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Fosun PharmaSoutheast UniversityLeading hospitals in China
Beyond the preview
Go deeper on Otovia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Otovia Therapeutics.